Dare Bioscience, Inc. (DARE) Stock Price & Analysis

Dare Bioscience, Inc. (DARE) rose 1.59% to USD 1.28 as of July 25, 2026 at 06:13 UTC, according to Nexqual real-time market data.

DARE last closed at USD 1.26; the session ranged USD 1.23–1.34 on volume of 195,511 shares. Market capitalization is $19.17M, with a 52-week range of USD 1.16–3.78 (NCM). Source: Nexqual, July 25, 2026 at 06:13 UTC.

Key Statistics (as of July 25, 2026 at 06:13 UTC)

Technical Analysis (DARE)

Nexqual's technical model rates DARE "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 06:13 UTC.

Analyst Ratings (DARE)

Wall Street analysts rate DARE "None" based on 3 analysts, with a mean price target of USD 9.67 (range USD 8–12), per Nexqual as of July 25, 2026 at 06:13 UTC.

Earnings (DARE)

Recent Earnings History

Source: Nexqual, July 25, 2026 at 06:13 UTC.

Financials & Fundamentals (DARE)

Source: Nexqual, July 25, 2026 at 06:13 UTC.

Financial Health Score (DARE)

Nexqual rates Dare Bioscience, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 06:13 UTC.

Ownership (DARE)

Source: Nexqual, July 25, 2026 at 06:13 UTC.

Leadership (DARE)

Dare Bioscience, Inc. is led by Sabrina Martucci Johnson (age 58), CEO, President, Principal Financial Officer, Secretary & Director, per Nexqual as of July 25, 2026 at 06:13 UTC.

Major Backers & Investors (DARE)

Notable institutional backers of Dare Bioscience, Inc. include Fidelity, US BANCORP \DE\, UBS Group AG, according to Nexqual as of July 25, 2026 at 06:13 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, July 25, 2026 at 06:13 UTC.

From Dare Bioscience, Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)

Key Strengths & Strategy (as disclosed to the SEC)

• In assessing which of our proprietary formulations are candidates for Section 503B compounding, in addition to the drug substance(s) being on the FDA's interim 503B Category 1 list of bulk drug substances, we take into account whether we believe the formulation is ready for cGMP manufacturing at scale to meet potential market demand and that the data from nonclinical and clinical studies of the formulation to date will be compelling to healthcare providers.
• For select proprietary formulations, we are pursuing both traditional FDA approval and earlier market access via outsourcing facilities registered under Section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA), which may compound and distribute certain drugs without patient-specific prescriptions.
• We do not believe bringing our select proprietary formulations to market via Section 503B compounding will negatively impact the regulatory process or commercial opportunity for an FDA-approved product utilizing the same proprietary formulation.
• As a compounded drug, DARE to PLAY is not covered by insurance and is not eligible for reimbursement through government or commercial health plans, including Medicare and Medicaid, or under insurance formularies applicable to FDA-approved prescription drug products.

Partnerships

• In 2022, we entered into an agreement with an affiliate of Organon & Co., Organon International GmbH, or Organon, whereby Organon licensed exclusive worldwide rights to develop, manufacture and commercialize XACIATO.
• We previously were also collaborating on Ovaprene with Bayer Healthcare LLC, or Bayer, under a license agreement entered into in January 2020.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:13 UTC. This page is informational and not investment advice.